Quantcast

Latest Myelodysplastic syndrome Stories

2014-09-09 08:32:43

SAN DIEGO, Sept. 9, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced results for its fiscal year ended June 30, 2014. "I am very proud of all that we have accomplished over the past year, highlighted by significant progress toward the clinical development of our lead drug candidate Pracinostat," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "Now we...

2014-09-03 04:21:54

AMSTERDAM, September 3, 2014 /PRNewswire/ -- ~ Clinical and Business Development expert re-joins the Company ~ Kiadis Pharma B.V. ("Kiadis Pharma", "Kiadis" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most recently Chief Medical Officer at Ceronco Biosciences. Prior...

2014-09-02 08:30:36

Data from Multi-Center, Placebo-Controlled Study Anticipated in Q1 2015 SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk...

2014-08-29 12:24:42

PISCATAWAY, N.J., Aug. 29, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN®. InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United...

2014-08-26 16:28:30

- New first-in-class treatment option for this previously treated SAA patient population LONDON, Aug. 26, 2014 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta(®) (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).(1) SAA is a blood disorder...

2014-08-11 08:28:56

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations. Mocetinostat is being...

2014-08-08 11:12:02

AGA Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease (IBD) patients. These data were reported in a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA). Thiopurines are an established treatment for...

2014-08-06 08:33:56

Live Webcasts from New York on August 13th and Boston on August 14th SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: -- The Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 9:10 a.m. Eastern...

2014-07-28 08:28:49

TORONTO, July 28, 2014 /PRNewswire/ - Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multi-center, open-label,...

2014-07-24 16:26:56

HILDEN, Germany, and MARSEILLE, France, July 24, 2014 /PRNewswire/ -- - Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers - Mutations of SF3B1 gene, to be targeted by new test, indicate favorable prognosis for patients with bone marrow disorders known as myelodysplastic syndromes - QIAGEN...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'